Malignant Fibrous Histiocytoma

This is a type of cancer (malignant) that starts in the soft tissues of the body. It's a serious condition that needs medical treatment.

Condition

What people with Malignant Fibrous Histiocytoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Radiation Therapy for Malignant Fibrous Histiocytoma?

NameHow it went

About Malignant Fibrous Histiocytoma

What It Is

Malignant fibrous histiocytoma is the older name for a cancer now called undifferentiated pleomorphic sarcoma (UPS). It is a soft tissue sarcoma: a cancer that starts in the tissues that connect and support the body, such as muscle, fat and fibrous tissue. It most often appears as a lump in an arm, a leg or the trunk, and the lump may be painless at first. The old name suggested the tumor came from histiocytes, a type of immune cell. Pathologists no longer think so, and where these cells come from is still unknown. The new name describes what is seen under the microscope instead: "undifferentiated" means the cells have not matured into any recognizable tissue type, and "pleomorphic" means they vary widely in size and shape. Sarcomas are uncommon cancers, but UPS is one of the more common types in adults, making up roughly 1 in 7 soft tissue sarcomas. It is usually diagnosed between the ages of 60 and 70. UPS is almost always high grade, which means it tends to grow quickly and has a real chance of spreading, most often to the lungs.

Causes & Risk Factors

In most people, no cause is found. A few factors are known to raise the risk. Past radiation therapy is the best recognized. UPS can occasionally develop inside an area that was treated with radiation for an earlier cancer, typically many years later; in one series of cases after breast cancer treatment, the gap was 6 to 17 years. Certain inherited conditions that raise the risk of soft tissue sarcomas in general, such as Li-Fraumeni syndrome and neurofibromatosis type 1, also play a part for some people. An injury sometimes draws attention to a lump, and the old belief that injuries can trigger this cancer still circulates. Injury is not an established risk factor; most often the bump simply makes someone notice a lump that was already there.

How It's Diagnosed

Imaging usually comes first. An MRI or CT scan shows how large and how deep the lump is and how close it sits to muscles, nerves and blood vessels, which also shapes any later surgery. The diagnosis itself requires a biopsy, most often a core needle biopsy, in which a wide needle removes several thin samples of tissue, sometimes guided by ultrasound, CT or MRI. Ideally the biopsy is planned together with the surgeon and radiation oncologist who may treat the tumor later. A pathologist, a doctor who diagnoses disease from tissue, then examines the samples and runs special stains and genetic tests. Because sarcomas are uncommon and hard to classify, the tissue should be reviewed by a pathologist experienced in sarcoma. UPS is largely a diagnosis of exclusion. The pathologist reaches it when the tumor has the typical disorganized, varied appearance and the tests find no features of a more specific sarcoma or another kind of cancer. The pathologist also assigns a grade, which reflects how abnormal the cells look and how fast they are dividing; UPS is nearly always high grade. Because high-grade sarcomas most often spread to the lungs, a chest CT scan is a standard part of staging, the process of working out how far the cancer has spread.

Treatment Options

When UPS has not spread, the main treatment is surgery to remove the whole tumor along with a margin of healthy tissue around it. In an arm or leg this can usually be done while saving the limb, and amputation is rarely needed. Because UPS is high grade, radiation therapy is usually added to lower the chance of the cancer coming back in the same place. It can be given before surgery, which uses a smaller area and dose but roughly doubles the rate of wound-healing problems, or after surgery, which heals more easily but is more likely to leave lasting stiffness, weakness and swelling. Both approaches control the tumor about equally well, so the choice depends on where the tumor is and how the surgery is planned. Chemotherapy has a less settled role. The usual first choice is doxorubicin combined with ifosfamide, two older chemotherapy drugs used across many sarcomas. It is mainly used when the cancer has spread or has high-risk features, but experts disagree about how much it helps, and its side effects can be hard to tolerate, especially for older adults. Immunotherapy is the most active area of change. UPS responds better than most sarcomas to immune checkpoint inhibitors, drugs that release a brake on the immune system so it can attack the cancer. In a randomized trial of people with high-risk UPS and similar sarcomas of the arm or leg, adding pembrolizumab (Keytruda) to radiation and surgery raised the share who were free of cancer two years later from about half to about two thirds. When the cancer has spread or cannot be removed, pembrolizumab alone shrank tumors in about 1 in 4 people with UPS in an early trial. Not everyone benefits, there is no reliable test yet to predict who will, and these drugs can cause the immune system to inflame healthy organs such as the lungs, bowel, liver or hormone glands. Clinical trials are an option worth asking about at any stage. If the cancer spreads to the lungs in only a few spots and the original tumor is under control, surgery to remove those spots can sometimes lead to long-term control.

What to Expect

Treatment for UPS that has not spread usually stretches over a few months, with radiation given in daily sessions over several weeks either before or after surgery. Recovery depends heavily on where the tumor was and how much tissue had to be removed. Some people regain near-normal use of the area, while others live with lasting stiffness, weakness or swelling in the treated limb. UPS is an aggressive cancer, and the outlook varies with the tumor's size, depth and location, whether it was removed completely and whether it had already spread. Across studies, roughly 60 to 70 percent of people are alive five years after diagnosis. When the cancer has spread to other organs, five-year survival is around 20 percent. These figures describe groups of people treated in the past and cannot predict any one person's course. The main concern after treatment is the cancer returning, either at the original site or in the lungs. More than 80 percent of returns happen within the first two years, so follow-up is closest then, with regular examinations of the treated area and chest imaging to look for spread to the lungs. Returns at the original site are usually found by examination rather than scans. Later recurrences do happen, so checkups continue for years.

When to Seek Help

See a clinician about any lump in an arm, leg or the trunk that is new, growing or persistent, even if it does not hurt. A suspicious lump is best imaged and biopsied before anyone tries to remove it, because cutting into a sarcoma or shelling it out without a plan raises the chance of it coming back. After treatment, contact your care team promptly about a new lump or swelling at or near the treated site, a new cough or shortness of breath that does not settle, or a surgical wound that opens, leaks or becomes increasingly red and painful. During immunotherapy, report new diarrhea, a new cough or breathlessness, or other new symptoms to the treating team right away, since these can be early signs of immune-related inflammation.

Questions to Ask Your Doctor

  1. 1.Has a pathologist experienced in sarcoma confirmed that this is undifferentiated pleomorphic sarcoma rather than another type of tumor?
  2. 2.Would radiation before or after surgery suit my tumor's location, and how would each affect healing and long-term use of that area?
  3. 3.Is chemotherapy or immunotherapy such as pembrolizumab worth considering in my situation, and are there clinical trials I could join?
  4. 4.How often will I need scans and checkups after treatment, and which changes should prompt me to call between visits?
  5. 5.How many people with sarcoma does this team treat, and would a second opinion at a sarcoma center be useful?

Last reviewed • Oct 2026

Educational content, not medical advice.